Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: while Q4 revenue declined due to external factors like a government shutdown, gross margins and EBITDA improved due to cost reductions. The Q&A reveals potential growth in key product lines and a strong backlog. However, uncertainties like NIH funding delays and macroeconomic risks persist. The company's flexible debt structure and positive guidance for 2026 products are offset by operational risks from facility consolidation and increased employee compensation costs. Overall, the sentiment is neutral, with no strong catalysts for significant stock price movement.
Key Financial Performance
Revenue (Q4 2025) $23.7 million, a decrease from $24.6 million in Q4 2024. The decline was attributed to a 43-day government shutdown that impacted performance.
Gross Margin (Q4 2025) 59.7%, an increase of 260 basis points from 57.1% in Q4 2024. The improvement was driven by cost actions taken in 2024 and 2025, as well as higher-margin NPI revenue.
Adjusted EBITDA (Q4 2025) $3.8 million, a 27% year-over-year increase. This was due to cost reductions, including decreased costs related to manufacturing and SG&A headcount, as well as expense management.
Revenue (Full Year 2025) $86.6 million, a decrease from $94.1 million in 2024. The decline was primarily due to the impact of tariffs and delayed NIH funding.
Gross Margin (Full Year 2025) 57.7%, a slight decrease from 58.2% in 2024. The decline was due to lower revenue, but partially offset by cost actions in manufacturing.
Adjusted EBITDA (Full Year 2025) $8.1 million, a 12.5% increase from $7.2 million in 2024. The improvement was driven by cost reductions, improved expense management, and strong execution.
Operating Income (Q4 2025) $1.7 million, an increase from flat in Q4 2024. Adjusted operating income was $3.3 million, up from $2.5 million last year, driven by cost reductions in manufacturing and SG&A.
Operating Income (Full Year 2025) Negative $48.6 million, a decline from negative $6.2 million in 2024. Adjusted operating income was $6.2 million, up from $5.3 million, due to cost reductions and favorable product mix.
Cash Flow from Operations (Full Year 2025) $6.7 million, a significant increase from $1.4 million in 2024. The improvement was due to disciplined working capital management, improved operating income, and payroll tax refunds.
Net Debt (End of 2025) $31.4 million, a reduction of $1.8 million from 2024. This was due to payments on prior syndicated debt and additional liquidity from a new agreement.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Innovation (NPI): Focused on scalable, differentiated platforms such as SoHo telemetry, BTX for bioproduction, Mesh MEA, and Incub8. These platforms aim to modernize preclinical and translational workflows.
Translational Science Market: Positioning products into the $10 billion translational science market by evolving from a traditional life science tools provider to a leading enabler of translational science.
Manufacturing Consolidation: Phased closure of the Holliston facility and consolidation into Minneapolis and European centers of excellence, expected to generate $3 million in savings in 2027 and $4 million thereafter.
Cost Reductions: Achieved through disciplined expense management, reduced manufacturing and SG&A headcount, and operational efficiencies, contributing to improved gross margins and adjusted EBITDA.
Strategic Shift to Translational Science: Evolving from a traditional life science tools provider to a translational science enabler, focusing on bridging in vivo and in vitro research to improve drug development efficiency.
Governance and Leadership Enhancements: Appointed 4 new Board members, established a product and Scientific Advisory Board, and solidified executive leadership with the appointment of Mark Frost as CFO.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Government Shutdown Impact: The 43-day government shutdown negatively impacted the company's ability to achieve higher revenue in Q4 2025.
NIH Funding Delays: Delays in NIH funding affected the timing of orders, particularly for preclinical telemetry products, impacting revenue for the full year 2025.
Tariff Impacts: Tariffs negatively affected revenue earlier in 2025, though the impact subsided later in the year.
Lower Academic Sales: Declines in academic sales in the Americas and Europe contributed to lower revenues in these regions for both Q4 and the full year 2025.
Goodwill Impairment: A goodwill impairment charge earlier in the year significantly impacted GAAP operating income and EPS for 2025.
Macroeconomic Volatility: Global macroeconomic conditions remain a concern, with potential impacts on revenue and operational performance.
Manufacturing Consolidation Risks: The phased closure of the Holliston facility and consolidation into other centers may pose operational risks during the transition period.
Employee Compensation Reinstatement: Reinstating bonuses and merit-based compensation in 2026 will increase costs, potentially impacting adjusted EBITDA growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth for 2026: The company expects revenue growth of 2% to 4% for the full year 2026, with revenue ramping throughout the year supported by stronger NPI (New Product Innovation) revenue.
Adjusted EBITDA Growth for 2026: Adjusted EBITDA is projected to grow by 6% to 10% in 2026, driven by higher-margin NPI growth and operational efficiency.
Gross Margin for 2026: The company anticipates gross margins to be in the range of 58% to 60% for the full year 2026.
Q1 2026 Guidance: Revenue is expected to be between $20 million and $22 million, adjusted gross margin between 57% and 59%, and adjusted EBITDA between $1 million and $2.2 million.
Market Trends and Strategic Focus: The company is focusing on the $10 billion translational science market, evolving from a traditional life science tools provider to a leading enabler of translational science. This includes strengthening its position in preclinical and organoid-based research and prioritizing high-margin consumables, service, and software to improve revenue visibility and gross margins.
Operational Efficiency: The company plans to continue cost discipline and operational efficiency, supported by manufacturing consolidation and refinancing, to fund innovation and improve profitability.
NIH Funding and Macro Conditions: The company is monitoring NIH funding timing and global macroeconomic conditions, which could impact order timing and revenue.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Regarding the NIH approval on February 3, how quickly will it improve the academic environment?
A:The company expects to see a positive impact towards the end of Q1 and into Q2, as grant submissions are approved and orders improve.
Q:What percentage of the company's revenue comes from NIH?
A:NIH revenue is about 20% of the company's U.S. revenue.
Q:What is the expected growth for BTX and Mesh MEA products in 2026?
A:Both products are expected to grow in double digits this year.
Q:Is there a quarterly paydown of debt planned for this year?
A:The debt structure allows flexibility with no amortization in the first 2 years. Term Loan A can be converted to an ABL for lower interest and flexibility, and Term Loan C could potentially be converted to equity to reduce leverage.
Q:Is the increase in Asia Pac revenue a sign of a turnaround, and what are the expectations for 2026?
A:The company has seen improvement after tariffs impacted the China business last year. Orders were filled in Q4, and they expect to return to a normal cadence in Asia unless tariffs change.
Q:Have there been any changes in the backlog during the fourth quarter?
A:The company ended the year with the highest backlog in over 2 years and has maintained it.
Q:How is the demand for products in the pharmaceutical biotech CRO side of the business?
A:The pharma and biotech business is up year-to-date, and the company expects this trend to continue, which is reflected in their guidance for the year.
Q:Review of Unclear Management Responses
A:Management avoided directly answering the question about quarterly debt paydown, instead discussing the flexibility of the debt structure without providing specific plans for paydown.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advisory
Conference
Frost Chief
Full
Harvard Bioscience
NPI
Securities
action
company
condition
consolidation
consumables
development
digit
employee
evolution
excellence
flexibility
footprint
foundation
industry
life science
line
manufacturing
margin product
measure
mix shift
model
platform
position
press release
priority
provider
refinancing
research
saving
science market
service
shift margin
telemetry
today press
HBIO Transcript
Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript
Unknown3-12
The earnings call presents mixed signals: while Q4 revenue declined due to external factors like a government shutdown, gross margins and EBITDA improved due to cost reductions. The Q&A reveals potential growth in key product lines and a strong backlog. However, uncertainties like NIH funding delays and macroeconomic risks persist. The company's flexible debt structure and positive guidance for 2026 products are offset by operational risks from facility consolidation and increased employee compensation costs. Overall, the sentiment is neutral, with no strong catalysts for significant stock price movement.
OceanaGold Corporation (OGC:CA) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call reflects a positive sentiment with strong financial performance, including increased EBITDA, net profit, and EPS. Despite some uncertainties in CapEx and costs, the company shows confidence in resolving issues and improving production. The anticipated strong Q4 and optimistic 2026 outlook, alongside potential cost reductions and share buybacks, support a positive stock price movement.
Harvard Bioscience, Inc. (HBIO) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call presents a mixed picture. Financial performance shows positive elements like high gross margins and improved EBITDA, yet revenue declined YoY. Challenges such as NIH funding delays, China market struggles, and tariff impacts create uncertainties. However, optimistic guidance and product development initiatives provide potential upside. The Q&A reveals cautious optimism but highlights risks like NIH funding delays. Overall, the sentiment is neutral due to balanced positive and negative factors, with no strong catalysts to drive significant stock price movement in the short term.
Harvard Bioscience, Inc. (HBIO) Q2 2025 Earnings Call Transcript
Unknown8-11
Despite some positive elements like cost reduction and improved cash flow, the overall sentiment is negative due to the revenue decline, gross margin pressure, debt risks, and macroeconomic uncertainties, including tariffs and NIH funding delays. The Q&A section highlighted concerns about debt refinancing and unclear guidance on NIH budget impacts. Given these factors, along with the lack of a clear positive catalyst, the stock price is likely to experience a negative movement in the next two weeks.
HBIO Slides
Harvard Bioscience Q4 2025 slides: margins hit 7-quarter high2026-03-12
Harvard Bioscience Q3 2025 slides: EPS miss overshadows operational improvements2025-11-06
Harvard Bioscience Q2 2025 slides: improved profitability despite revenue challenges2025-08-11
Harvard Bioscience Q1 2025 slides: Revenue decline and goodwill impairment weigh on results2025-05-12
HBIO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
